| abstract |
The present disclosure provides a modified vaccinia ankara, delivered as an anti-cancer immunotherapeutic agent alone or in combination with one or more immune checkpoint blockers, intratumorally or systemically for the treatment of malignant solid tumors. MVA) virus or MVAAE3L. A specific embodiment relates to mobilizing the host immune system to increase the immune response against the tumor. |